Cullinan Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cullinan Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 93% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-225.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 93% of Healthcare companies in United States.
Cash Cushion Ratio
+41%Cash, after subtracting all debt, equals 41% of its market value (net cash).
Higher than 74% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Cullinan Therapeutics, Inc. made a loss over the last year. Cullinan Therapeutics, Inc. owes $0.12 for every $1 it owns. Cullinan Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCullinan Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.85The share price is 2.85 times Cullinan Therapeutics, Inc.'s book value per share, higher than 54% of Healthcare companies in United States.
Market cap
$917 MThe total market value of all of Cullinan Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 62% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$322 MWhat Cullinan Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$5.24Net worth divided by the number of shares. The share price of $14.92 is 2.8 times this, which is the P/B above.
Return on equity (ROE)
-50.3%Cullinan Therapeutics, Inc. lost 50.3% of its shareholders' money over the last year, lower than 52% of Healthcare companies in United States.
Owes vs Owns
0.12×Cullinan Therapeutics, Inc. owes $0.12 for every $1 it owns (low), lower than 84% of Healthcare companies in United States.
Dividend yield
NoneCullinan Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossCullinan Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashCullinan Therapeutics, Inc. held $375 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Cullinan Therapeutics, Inc.: $917 M ÷ $322 M (30 Jun 2026) = 2.8.
What is Cullinan Therapeutics, Inc.'s return on equity?
Cullinan Therapeutics, Inc. lost 50.3% of its shareholders' money over the last year, lower than 52% of Healthcare companies in United States.
How much does Cullinan Therapeutics, Inc. owe compared with what it owns?
Cullinan Therapeutics, Inc. owes $0.12 for every $1 it owns (low), lower than 84% of Healthcare companies in United States.
Does Cullinan Therapeutics, Inc. pay a dividend?
No. Cullinan Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.